Ikena Oncology (IKNA) investor relations material

Executive summary

• Entered into a merger agreement with Inmagene Biopharmaceuticals, with stockholder approval obtained in July 2025; closing expected by end of July, subject to remaining conditions.

• Discontinued development of IK-930 and began winding down IK-595 clinical program in July 2025, shifting focus to strategic alternatives and asset divestitures.

• Net loss for the six months ended June 30, 2025 was $11.4 million, a significant improvement from $29.9 million in the same period last year.

• Cash, cash equivalents, and marketable securities totaled $95.6 million as of June 30, 2025, expected to fund operations for at least 12 months if the merger is not consummated.

• Company’s future operations are highly dependent on successful completion of the merger or another strategic transaction.

Financial highlights

• Net loss for Q2 2025 was $2.8 million, compared to $13.8 million in Q2 2024; six-month net loss was $11.4 million, down from $29.9 million year-over-year.

• Operating expenses for the six months ended June 30, 2025 decreased 43% year-over-year to $19.5 million, driven by lower R&D and G&A costs.

• Research and development expenses fell 60% year-over-year to $7.7 million for the six months ended June 30, 2025.

• General and administrative expenses decreased 11% year-over-year to $10.1 million for the six months ended June 30, 2025.

• Other income for the six months ended June 30, 2025 was $8.2 million, including $4.3 million in R&D reimbursements and $0.8 million in sublease income.

Outlook and guidance

• If the merger closes, the combined company will focus on advancing Inmagene’s lead candidate, IMG-007, in atopic dermatitis and other immunology indications.

• If the merger or another strategic transaction is not completed, the board may pursue dissolution and liquidation, with cash available for distribution dependent on timing and liabilities.

• Ongoing costs expected for merger-related activities and strategic review; additional funding may be needed if development resumes.